Top

Published in:

01-06-2021 | Prostate Cancer | Editorial

A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis

Authors: Anwar R. Padhani, Ivo G. Schoots, Baris Turkbey, Gianluca Giannarini, Jelle O. Barentsz

Published in: European Radiology | Issue 6/2021

Key Points

• Identify, assure, and measure major sources of variability affecting the MRI-directed biopsy pathway for prostate cancer diagnosis.

• Develop strategies to control and minimize variations that impair pathway effectiveness including the performance of main players and team working.

• Assure end-to-end quality of the diagnostic chain with robust multidisciplinary team working.

Drost F-JH, Osses D, Nieboer D et al (2020) Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis. Eur Urol 77:78–94. https://doi.org/10.1016/j.eururo.2019.06.023CrossRefPubMed

van der Leest M, Cornel E, Israël B et al (2019) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 75:570–578. https://doi.org/10.1016/j.eururo.2018.11.023CrossRefPubMed

Sokhi HK, Padhani AR, Patel S, Pope A (2020) Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice. Clin Radiol. https://doi.org/10.1016/j.crad.2020.08.011

Boesen L, Nørgaard N, Løgager V et al (2018) Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men. JAMA Netw Open 1:e180219. https://doi.org/10.1001/jamanetworkopen.2018.0219CrossRefPubMedPubMedCentral

Rouvière O, Puech P, Renard-Penna R et al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20:100–109. https://doi.org/10.1016/S1470-2045(18)30569-2CrossRefPubMed

Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777. https://doi.org/10.1056/NEJMoa1801993CrossRefPubMed

Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822. https://doi.org/10.1016/S0140-6736(16)32401-1CrossRefPubMed

Zawaideh JP, Sala E, Shaida N et al (2020) Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice. Eur Radiol. https://doi.org/10.1007/s00330-020-06782-0

US Preventive Services Task Force, Grossman DC, Curry SJ et al (2018) Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 319:1901–1913. https://doi.org/10.1001/jama.2018.3710CrossRef

10.

Sathianathen NJ, Omer A, Harriss E et al (2020) Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis. Eur Urol 78:402–414. https://doi.org/10.1016/j.eururo.2020.03.048CrossRefPubMed

11.

Stonier T, Simson N, Shah T, et al (2020) The ‘Is mpMRI Enough’ or IMRIE study: a multicentre evaluation of prebiopsy multiparametric magnetic resonance imaging compared with biopsy. Eur Urol Focus 1–9. https://doi.org/10.1016/j.euf.2020.09.012

12.

Simmons LAM, Kanthabalan A, Arya M et al (2017) The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. Br J Cancer 116:1–7. https://doi.org/10.1038/bjc.2017.57CrossRef

13.

Mottet N, van den Bergh RC, Briers E et al (2019) 2019 EAU - EANM - ESTRO - ESUR - SIOG guidelines on prostate cancer. EAU Guidelines Office, Arnhem

14.

NICE, NATIONAL INSTITUTE FOR HEALTH AND CARE (2019) National Institute for Heath and care Excellence. Prostate cancer : diagnosis and management (update) https://doi.org/10.5094/apr.2010.001

15.

Padhani AR, Barentsz J, Villeirs G et al (2019) PI-RADS Steering Committee: the PI-RADS multiparametric MRI and MRI-directed biopsy pathway. Radiology 292:464–474. https://doi.org/10.1148/radiol.2019182946CrossRefPubMedPubMedCentral

16.

Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340–351. https://doi.org/10.1016/j.eururo.2019.02.033CrossRefPubMed

17.

de Rooij M, Israël B, Barrett T et al (2020) Focus on the quality of prostate multiparametric magnetic resonance imaging: synopsis of the ESUR/ESUI recommendations on quality assessment and interpretation of images and radiologists’ training. Eur Urol 78:483–485. https://doi.org/10.1016/j.eururo.2020.06.023CrossRefPubMed

18.

Giganti F, Allen C, Emberton M, Moore CM, Kasivisvanathan V, PRECISION study group (2020) Prostate imaging quality (PI-QUAL): a new quality control scoring system for multiparametric magnetic resonance imaging of the prostate from the PRECISION trial. Eur Urol Oncol 3:615–619. https://doi.org/10.1016/j.euo.2020.06.007

19.

Schelb P, Kohl S, Radtke JP et al (2019) Classification of cancer at prostate MRI: deep learning versus clinical PI-RADS assessment. Radiology 190938. https://doi.org/10.1148/radiol.2019190938

20.

Padhani AR, Barentsz JO, Weinreb J, Schoots I, Tempany C (2020) Re: variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Eur Urol 296:633–636. https://doi.org/10.1016/j.eururo.2020.06.015

21.

Park KJ, Choi SH, Lee JS, Kim JK, Kim MH, Jeong IG (2020) Risk stratification of prostate cancer according to PI-RADS version 2 categories: meta-analysis for prospective studies. J Urol. https://doi.org/10.1097/JU.0000000000001306

22.

Schoots IG, Padhani AR (2020) Risk-adapted biopsy decision based on prostate MRI and PSA-density for enhanced biopsy avoidance in first prostate cancer diagnostic work-up. Br J Urol Int. https://doi.org/10.1111/bju.15277

23.

Goldberg H, Ahmad AE, Chandrasekar T et al (2020) Comparison of magnetic resonance imaging and transrectal ultrasound informed prostate biopsy for prostate cancer diagnosis in biopsy naïve men: a systematic review and meta-analysis. J Urol 203:1085–1093. https://doi.org/10.1097/JU.0000000000000595CrossRefPubMed

24.

Stabile A, Giganti F, Kasivisvanathan V et al (2020) Factors influencing variability in the performance of multiparametric magnetic resonance imaging in detecting clinically significant prostate cancer: a systematic literature review. Eur Urol Oncol 3:145–167. https://doi.org/10.1016/j.euo.2020.02.005CrossRefPubMed

25.

Venderink W, Bomers JG, Overduin CG et al (2020) Multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer: what urologists need to know. Part 3: targeted biopsy. Eur Urol 77:481–490. https://doi.org/10.1016/j.eururo.2019.10.009CrossRefPubMed

26.

Luzzago S, Petralia G, Musi G et al (2019) Multiparametric magnetic resonance imaging second opinion may reduce the number of unnecessary prostate biopsies: time to improve radiologists’ training program? Clin Genitourin Cancer 17:88–96. https://doi.org/10.1016/j.clgc.2018.10.006CrossRefPubMed

27.

Lamb BW, Jalil RT, Sevdalis N, Vincent C, Green JS (2014) Strategies to improve the efficiency and utility of multidisciplinary team meetings in urology cancer care: a survey study. BMC Health Serv Res 14:377. https://doi.org/10.1186/1472-6963-14-377

28.

Sciarra A, Gentile V, Panebianco V (2013) Multidisciplinary management of prostate cancer: how and why. Am J Clin Exp Urol 1:12–17PubMedPubMedCentral

29.

Schoots IG, Padhani AR (2020) Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated? World J Urol 38:531–545. https://doi.org/10.1007/s00345-019-02899-0CrossRefPubMed

30.

Cuocolo R, Stanzione A, Ponsiglione A et al (2019) Prostate MRI technical parameters standardization: a systematic review on adherence to PI-RADSv2 acquisition protocol. Eur J Radiol 120:108662. https://doi.org/10.1016/j.ejrad.2019.108662CrossRefPubMed

31.

Park KJ, Choi SH, Lee JS, Kim JK, Kim MH (2020) Interreader agreement with prostate imaging reporting and data system version 2 for prostate cancer detection: a systematic review and meta-analysis. J Urol 204:661–670. https://doi.org/10.1097/JU.0000000000001200

Title: A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis
Authors: Anwar R. Padhani
Ivo G. Schoots
Baris Turkbey
Gianluca Giannarini
Jelle O. Barentsz
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Published in: European Radiology / Issue 6/2021
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-020-07527-9

At a glance: The STEP trials

Springer Medicine

A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis

Key Points

At a glance: The STEP trials

Springer Medicine

Key Points

Please log in to get access to this content

Other articles of this Issue 6/2021

Correction to: Risk assessment of acute pulmonary embolism utilizing coronary artery calcifications in patients that have undergone CT pulmonary angiography and transthoracic echocardiography

Correction to: Diagnostic accuracy of spleen stiffness to evaluate portal hypertension and esophageal varices in chronic liver disease: a systematic review and meta-analysis

Evaluation of competence in ultrasound-guided procedures—a generic assessment tool developed through the Delphi method

Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib

To buy or not to buy—evaluating commercial AI solutions in radiology (the ECLAIR guidelines)

Chest CT–derived pulmonary artery enlargement at the admission predicts overall survival in COVID-19 patients: insight from 1461 consecutive patients in Italy